Medtronic Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 5/6

Medtronic kazançlarla iyi bir şekilde karşılanan, 3.17% cari getiriye sahip, temettü ödeyen bir şirkettir.

Anahtar bilgiler

3.2%

Temettü verimi

2.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	5.5%
Gelecekteki Temettü Verimi	3.3%
Temettü Büyümesi	7.8%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	77%

Son temettü ve geri alım güncellemeleri

Medtronic (NYSE:MDT) Will Pay A Larger Dividend Than Last Year At $0.71

May 30

Recent updates

Medtronic Stock: A Compelling Buy for Value and Income Investors as Robotics, Innovation Catalysts Ignite Upside to $105+

Feb 17Strengths and Competitive Advantages:Diverse Product Portfolio: Medtronic operates across four key segments—Cardiovascular, Medical-Surgical, Neuroscience, and Diabetes—providing revenue stability and

Medtronic (NYSE:MDT) Has More To Do To Multiply In Value Going Forward

Feb 17

Medtronic: Several Reasons For Optimism Before The Upcoming Earnings Release

Feb 15

Medtronic: Undervalued But Underperforming - Why Innovation Isn't Enough To Lift The Stock

Feb 07

We Think Medtronic (NYSE:MDT) Can Stay On Top Of Its Debt

Jan 20

Medtronic: A Dividend Aristocrat That's Poised To Pop

Jan 06

Investors Appear Satisfied With Medtronic plc's (NYSE:MDT) Prospects

Jan 06

Medtronic Stock Is Still A Great "Buy"

Dec 26

Medtronic (NYSE:MDT) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Dec 03

Medtronic Q3 Earnings: A Solid Performance, But Bottom Line Still Needs Fixing

Nov 19

Medtronic (NYSE:MDT) Hasn't Managed To Accelerate Its Returns

Nov 08

Medtronic: Undervalued But Trapped In Slow Growth (Rating Downgrade)

Oct 31

Is It Time To Consider Buying Medtronic plc (NYSE:MDT)?

Oct 13

Medtronic: Undervalued Dividend Aristocrat With High Margins

Oct 10

An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 33% Undervalued

Sep 30

Medtronic (NYSE:MDT) Boosts FY 2025 Guidance Amid Strong Q1 Earnings and Strategic Share Buybacks

Sep 16

Medtronic: An Undervalued Stock With Durable Competitive Advantages

Sep 16

Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly

Sep 05

Medtronic: Is The Company Back?

Aug 26

Medtronic: Still A Buy Before Earnings

Aug 17

Returns At Medtronic (NYSE:MDT) Appear To Be Weighed Down

Aug 08

Medtronic: An Out Of Favor Healthcare Stock With A Pulse On Profit Potential

Jul 16

Medtronic: Why I Disagree With The Crowd

Jun 14

Medtronic: Net Income Could Fall $3.38B, The Stock Would Still Be Undervalued

May 27

Medtronic Stock Looks Promising Before Fiscal Q4 2024 Release

May 13

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: MDT şirketinin hisse başına düşen temettüsü son 10 yıldır istikrarlıydı.

Büyüyen Temettü: MDT şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.

Piyasaya Karşı Temettü Getirisi

Medtronic Piyasaya Karşı Temettü Getirisi

MDT temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (MDT)	3.2%
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.6%
Sektör Ortalaması (Medical Equipment)	1.7%
Analist tahmini (MDT) (3 yıla kadar)	3.3%

Önemli Temettü: MDT 'in temettüsü ( 3.17% ), US piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 1.48% ) daha yüksektir.

Yüksek Temettü: MDT 'in temettüsü ( 3.17% ), US piyasasındaki temettü ödeyenlerin en üst %25'ine ( 4.59% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Mevcut ödeme oranı ( 77.2% ) ile MDT 'un ödemeleri kazançlarla karşılanmaktadır.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Makul nakit ödeme oranı ( 70.2% ) ile MDT 'un temettü ödemeleri nakit akışları ile karşılanmaktadır.

Güçlü temettü ödeyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/07/20 22:05
Gün Sonu Hisse Fiyatı	2025/07/18 00:00
Kazançlar	2025/04/25
Yıllık Kazançlar	2025/04/25

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Medtronic plc 64 Bu analistlerden 32, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Kadambari Daptardar	Accountability Research Corporation
Harshit Gupta	Accountability Research Corporation
David Toung	Argus Research Company

Medtronic Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 5/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Upcoming dividend of US$0.71 per share

Medtronic (NYSE:MDT) Will Pay A Larger Dividend Than Last Year At $0.71

Fourth quarter dividend increased to US$0.71

Medtronic plc Announces Cash Dividend for the First Quarter of Fiscal Year 2026, Payable on July 11, 2025

Upcoming dividend of US$0.70 per share

Third quarter dividend of US$0.70 announced

Recent updates

Medtronic Appoints Chad Spooner as Chief Financial Officer of MiniMed, Effective July 14, 2025

Medtronic's (NYSE:MDT) Returns On Capital Are Heading Higher

Medtronic: Eyes On The Pipeline And Spin, Shares Still Cheap

Medtronic plc Appoints Dr. Joon Lee as A New Director and Member of Science and Technology Committee and the Compensation and Talent Committee, Effective as of June 18, 2025

Full year 2025 earnings: EPS misses analyst expectations

Upcoming dividend of US$0.71 per share

A Look At The Fair Value Of Medtronic plc (NYSE:MDT)

Insider notifies of intention to sell stock

Medtronic (NYSE:MDT) Will Pay A Larger Dividend Than Last Year At $0.71

Fourth quarter dividend increased to US$0.71

Full year 2025 earnings: EPS misses analyst expectations

Medtronic plc Announces Cash Dividend for the First Quarter of Fiscal Year 2026, Payable on July 11, 2025

Medtronic plc Provides Earnings Guidance for the Fiscal Year 2026

Medtronic Expand URO U.S. Clinical Trial Meet Safety and Effectiveness Primary Endpoints for Hugo™ Robotic-Assisted Surgery System

Medtronic plc Receives FDA Approval for Smallest-Diameter, Lumenless Defibrillation Lead, the Omniasecure™ Lead and Announces Investigational Clinical Study Results

Medtronic plc Submits 510(K) Applications to U.S. Food and Drug Administration Seeking Clearance for Interoperable Pump

Medtronic: One Of The Best Times To Buy

Medtronic plc Announces U.S. Food and Drug Administration Approval for the Simplera Sync Sensor for Use with the MiniMed 780G System

Is Now An Opportune Moment To Examine Medtronic plc (NYSE:MDT)?

Medtronic plc Announces Late-Breaking Data on Five-Year Outcomes from the Evolut Low Risk Trial

Medtronic: A Great Business, But With Low Growth

Upcoming dividend of US$0.70 per share

Medtronic plc Announces Executive Changes

Medtronic: Strength In Cardiac Ablation Solutions, Upgrade To Buy

Medtronic plc Releases the Two-Year Results of the SMall Annuli Randomized To Evolut or SAPIEN Trial

Third quarter dividend of US$0.70 announced

Medtronic plc Announces Cash Dividend for Fourth Quarter of Fiscal Year 2025, Payable on April 11, 2025

Medtronic Earns U.S. FDA Approval for the World's First Adaptive Deep Brain Stimulation System for People with Parkinson's

Third quarter 2025 earnings: EPS misses analyst expectations

Medtronic plc Re-Iterates Earnings Guidance for the Full Year 2025

Medtronic Stock: A Compelling Buy for Value and Income Investors as Robotics, Innovation Catalysts Ignite Upside to $105+

Medtronic (NYSE:MDT) Has More To Do To Multiply In Value Going Forward

Medtronic: Several Reasons For Optimism Before The Upcoming Earnings Release

Medtronic: Undervalued But Underperforming - Why Innovation Isn't Enough To Lift The Stock

Medtronic plc to Report Q2, 2026 Results on Nov 18, 2025

Medtronic plc to Report Q1, 2026 Results on Aug 19, 2025

Insider notifies of intention to sell stock

Now 20% undervalued after recent price drop

Medtronic plc Announces Chief Financial Officer Changes, Effective March 3, 2025

We Think Medtronic (NYSE:MDT) Can Stay On Top Of Its Debt

Medtronic Announces CMS National Coverage Analysis for Symplicity™ Spyral Renal Denervation System

Medtronic: A Dividend Aristocrat That's Poised To Pop

Investors Appear Satisfied With Medtronic plc's (NYSE:MDT) Prospects

Medtronic Stock Is Still A Great "Buy"

Upcoming dividend of US$0.70 per share

Second quarter dividend of US$0.70 announced

Medtronic plc Announces Cash Dividend for Third Quarter of Fiscal Year 2025, Payable on January 10, 2025

Medtronic (NYSE:MDT) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Medtronic plc Receives FDA Clearance for New Inpen App, Pending the Way for Its Smart MDI System Launch with Simplera™? CGM

New minor risk - Earnings quality

Medtronic Q3 Earnings: A Solid Performance, But Bottom Line Still Needs Fixing

Medtronic (NYSE:MDT) Hasn't Managed To Accelerate Its Returns

CMS Grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral Renal Denervation Catheter

Medtronic: Undervalued But Trapped In Slow Growth (Rating Downgrade)

Medtronic plc Announces New, Long-Term Data from Its SPYRAL HTN-ON MED Clinical Trial

Medtronic plc Receives FDA Approval of Affera Mapping and Ablation System and Sphere-9 Catheter

Is It Time To Consider Buying Medtronic plc (NYSE:MDT)?

Medtronic: Undervalued Dividend Aristocrat With High Margins

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc Announces the Presentation of Clinical Study Results

An Intrinsic Calculation For Medtronic plc (NYSE:MDT) Suggests It's 33% Undervalued

Upcoming dividend of US$0.70 per share

Medtronic (NYSE:MDT) Boosts FY 2025 Guidance Amid Strong Q1 Earnings and Strategic Share Buybacks

Medtronic: An Undervalued Stock With Durable Competitive Advantages

Medtronic (NYSE:MDT) Seems To Use Debt Quite Sensibly

Consensus EPS estimates increase by 12%

Medtronic: Is The Company Back?

First quarter 2025 earnings: EPS exceeds analyst expectations

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2025